Clinical trials: Intestinal Transit
Cystic Fibrosis
Gut Imaging for Function & Transit in Cystic Fibrosis Study 1
Many people with Cystic Fibrosis (CF) are troubled by symptoms from their stomach and bowels: their gastrointestinal (GI) tract.
- Trial name
- GIFT-CF1 (NCT03566550)
- Testing
- MRI scans
- Where
- United Kingdom
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Nottingham University Hospitals NHS Trust
Constipation-predominant Irritable Bowel Syndrome
Cheno Effect on Transit in Health and IBS-C
The study hypothesis is that the naturally occurring bile acid, chenodeoxycholic acid, induces acceleration of colonic transit in health and in patients with constipation-predominant Irritable Bowel Syndrome (IBS-C).
- Trial name
- Chenotransit (NCT00912301)
- Testing
- Sodium chenodeoxycholate (NaCDC)
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Food Selection
Pilot Study Using a Wireless Motility Capsule
Research suggests dietary fiber may decrease transit time through the gastrointestinal tract. Research studies traditionally use radio-opaque markers to determine gastric emptying, colonic transit, and whole gut transit time.
- Trial name
- NCT01102894
- Testing
- SmartPill
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- University of Minnesota
Small Bowel Bacterial Overgrowth, Gastrointestinal Diseases
Transit Time and Bacterial Overgrowth Using SmartPill Capsule
The primary purpose of this exploratory study is to measure orocecal transit time using the SmartPill ambulant capsule technology and to compare this with the lactulose hydrogen breath test.
- Conditions
- Small Bowel Bacterial Overgrowth, Gastrointestinal Diseases, Stomach Diseases, Digestive System Diseases
- Trial name
- NCT00577772
- Testing
- Xifaxan, SmartPill, Lactulose hydrogen breath test (H_2BT)
- Where
- United States
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Effects of 2 Mu-opiates on Gastrointestinal Transit
Comparison of the Effects of Tapentadol and Oxycodone on Gastrointestinal and Colonic Transit in Humans
Tapentadol is FDA approved for the treatment of moderate to severe acute pain. Due to the dual mechanism of action as an opioid agonist and norepinephrine reuptake inhibitor, there is potential for off label use in chronic pain.
- Trial name
- tap-oxy (NCT01500317)
- Testing
- Tapentadol, Oxycodone
- Where
- United States
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic